Readoutin 14d
RayzeBio, Inc. — RYZ101
Phase 3 primary completion: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy.
- Date
- Dec 2026
- Type
- Readout
- Indication
- GEP-NET
Readoutin 14d
Phase 3 primary completion: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.